ScinoPharm Taiwan, Ltd. - Laporan Laba Rugi (TTM)

ScinoPharm Taiwan, Ltd.
TW ˙ TWSE ˙ TW0001789006
NT$ 19.30 ↑0.30 (1.58%)
2025-09-12
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi ScinoPharm Taiwan, Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 3,028 3,083 3,182 3,021 2,917 2,762 2,859 2,917 2,968 3,264 3,175 3,124 3,079 3,186 3,421 3,428 3,493 3,406 3,209 3,195
Change (%) 1.80 3.20 -5.04 -3.45 -5.30 3.50 2.03 1.73 9.99 -2.74 -1.60 -1.44 3.49 7.37 0.22 1.89 -2.48 -5.78 -0.46
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,691 1,765 1,744 1,684 1,712 1,482 1,646 1,695 1,748 2,013 1,977 1,990 1,954 1,970 2,095 2,095 2,112 2,106 2,035 1,991
Change (%) 4.43 -1.23 -3.41 1.66 -13.45 11.07 2.99 3.13 15.17 -1.78 0.62 -1.82 0.85 6.36 -0.02 0.82 -0.29 -3.40 -2.14
% of Revenue 55.82 57.27 54.81 55.75 58.70 53.64 57.57 58.11 58.91 61.68 62.29 63.69 63.45 61.83 61.26 61.11 60.47 61.83 63.39 62.32
Gross Operating Profit 1,338 1,317 1,438 1,337 1,205 1,280 1,213 1,222 1,219 1,251 1,197 1,134 1,125 1,216 1,325 1,333 1,381 1,300 1,175 1,204
Change (%) -1.53 9.14 -7.03 -9.88 6.28 -5.25 0.72 -0.21 2.57 -4.29 -5.26 -0.79 8.07 9.00 0.59 3.56 -5.83 -9.64 2.45
% of Revenue 44.18 42.73 45.19 44.25 41.30 46.36 42.43 41.89 41.09 38.32 37.71 36.31 36.55 38.17 38.74 38.89 39.53 38.17 36.61 37.68
SG&A 684 696 708 692 681 686 681 658 613 574 533 523 522 544 551 558 547 520 514 499
Change (%) 1.80 1.75 -2.34 -1.60 0.77 -0.67 -3.47 -6.75 -6.41 -7.18 -1.88 -0.12 4.14 1.41 1.11 -1.92 -4.94 -1.15 -2.83
% of Revenue 22.58 22.58 22.26 22.90 23.33 24.83 23.83 22.55 20.67 17.59 16.78 16.74 16.96 17.07 16.12 16.26 15.65 15.26 16.01 15.63
R&D 243 246 288 301 276 306 265 274 264 271 298 333 355 358 356 334 387 459 452 486
Change (%) 1.25 17.31 4.36 -8.21 10.84 -13.31 3.25 -3.50 2.65 10.01 11.73 6.37 0.87 -0.36 -6.41 16.15 18.55 -1.68 7.57
% of Revenue 8.01 7.97 9.06 9.95 9.46 11.08 9.28 9.39 8.91 8.31 9.40 10.67 11.52 11.23 10.42 9.73 11.09 13.49 14.07 15.21
OpEx 2,617 2,707 2,740 2,677 2,669 2,474 2,592 2,627 2,626 2,859 2,809 2,846 2,830 2,872 3,003 2,986 3,047 3,085 3,000 2,976
Change (%) 3.45 1.22 -2.32 -0.29 -7.31 4.80 1.32 -0.03 8.87 -1.75 1.33 -0.55 1.46 4.59 -0.57 2.02 1.27 -2.76 -0.80
% of Revenue 86.41 87.81 86.13 88.60 91.49 89.55 90.67 90.04 88.48 87.58 88.47 91.10 91.93 90.13 87.80 87.11 87.22 90.58 93.47 93.16
Operating Income 411 376 441 344 248 289 267 290 342 405 366 278 248 314 417 442 446 321 209 219
Change (%) -8.69 17.48 -21.97 -27.97 16.33 -7.60 8.91 17.69 18.63 -9.76 -24.04 -10.63 26.60 32.75 5.89 0.99 -28.09 -34.77 4.35
% of Revenue 13.59 12.19 13.87 11.40 8.51 10.45 9.33 9.96 11.52 12.42 11.53 8.90 8.07 9.87 12.20 12.89 12.78 9.42 6.53 6.84
Interest Expense -17 -15 -13 -10 -7 -7 -7 -7 -7 -8 -9 -9 -9 -9 -9 -8 -8 -8 -8 -8
Change (%) -9.09 -17.14 -21.51 -25.11 -11.36 1.95 4.34 4.81 8.38 7.89 5.58 2.55 -1.04 -4.06 -4.25 -3.69 -0.12 1.06 3.02
% of Revenue -0.55 -0.49 -0.39 -0.33 -0.25 -0.24 -0.23 -0.24 -0.25 -0.24 -0.27 -0.29 -0.30 -0.29 -0.26 -0.25 -0.23 -0.24 -0.25 -0.26
Net Income 323 282 337 266 198 243 230 254 305 353 318 261 231 287 385 403 399 339 245 205
Change (%) -12.60 19.46 -21.19 -25.46 23.01 -5.34 10.04 20.40 15.68 -9.98 -17.89 -11.43 24.13 34.14 4.66 -0.90 -15.03 -27.70 -16.58
% of Revenue 10.66 9.15 10.59 8.79 6.79 8.81 8.06 8.69 10.29 10.82 10.02 8.36 7.51 9.01 11.26 11.76 11.43 9.96 7.64 6.41

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista